Cette section contient plusieurs publications jugées intéressantes par le Groupe québécois de recherche en LMC-NMP


Publications sur la LMC


Li, Qianyin, et al. « Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells. » International Journal of Molecular Sciences 18.3 (2017): 537.

Laneuville, Pierre. « Stopping second-generation TKIs in CML. » Blood 129.7 (2017): 805-806.

Damlaj, Moussab, Jeffrey H. Lipton, and Sarit E. Assouline. « A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. » Expert Opinion on Drug Safety 15.9 (2016): 1279-1286.

Cortes, Jorge E., et al. « Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. » Clinical Lymphoma Myeloma and Leukemia 16.5 (2016): 286-296.

Engel, Nils W., et al. « Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia. » Journal of Oncology Practice (2016): JOPR012054.
Lipton, Jeffrey H., et al. « Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. » The Lancet Oncology 17.5 (2016): 612-621.
Mauro, Michael J., et al. « The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. » Therapeutic advances in hematology 6.1 (2015): 3-14.
Cortes, Jorge E., et al. « The impact of dasatinib on pregnancy outcomes. » American journal of hematology 90.12 (2015): 1111-1115.
Mori, Silvia, et al. « Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. » American journal of hematology 90.10 (2015): 910-914.

Publications sur la NMP


Mesa, Ruben A., et al. « Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. » The Lancet Haematology (2017).

Busque, Lambert, et al. « Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). » American Journal of Clinical Pathology 146.4 (2016): 408-422.
Gupta, Vikas, et al. « A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. » Haematologica 102.1 (2017): 94-102.
Arber, Daniel A., et al. « The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. » Blood (2016): blood-2016.
Tefferi, Ayalew. « Myeloproliferative neoplasms: a decade of discoveries and treatment advances. » American journal of hematology 91.1 (2016): 50-58.
Sirhan, Shireen, et al. « Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. » Clinical Lymphoma Myeloma and Leukemia 15.12 (2015): 715-727.
Savona, Michael R., et al. « An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. » Blood 125.12 (2015): 1857-1865.